Clinical Assessment of Voriconazole Self Nano Emulsifying Drug Delivery System Intermediate Gel

Tinea Versicolor Clinical Trial

Official title:

Clinical Evaluation of a Formulated Nanoemulsion for Topical Application

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04110860
• Other study ID #: VCZSaraSNEDDS
• Status: Completed
• Phase: Phase 2
• Start date: February 15, 2018
• Est. completion date: June 30, 2018

Study information

• Verified date: September 2019
• Source: Minia University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Clinical study for the developed voriconazole self nano emulsifying drug delivery system intermediate gel was conducted on 30 patients with tinea versicolor infection.

Description:

The clinical work has been carried out in accordance with The Code of Ethics of the World Medical Association for experiments involving humans. The study was conducted on 30 patients (10 to 60 years old) with tinea versicolor attending the dermatology department outpatient clinic of Minia University Hospital. Local institutional review board approval was obtained for this study (ethical approval number is 24/18). Pregnant or lactating females and Immunocompromized patients. The patients were then divided into 3 groups, placebo group, group A and group B, consisting of 10 patients each. The placebo group received unmedicated formulation, Group A received the medicated formulation once daily and group B were treated twice daily. An informed consent has been obtained from all patients enrolled in the study for photography and treatment. History and general local examination were performed for all patients.The patients were clinically examined under normal light and using wood's lamp and cello-tape test was performed to confirm infection after determining the type of infection and in some cases scrapes were taken to detect infection in clinically indefinite cases and stained using potassium hydroxide 20% then examined for presence of fungal elements. Treatment was performed by applying the gel once or twice daily until full recovery was achieved with follow up once a week to reassess the condition. The clinical improvement of the patients, patient satisfaction and length of treatment were assessed. It was rated by both patient and physician as excellent, good, fair or poor according to the following criteria. Excellent: both the patient and the physician agreed that the result was satisfactory. Good: the result although acceptable was not quite up to expectations, but the physicians were pleased with the outcome. Fair: the improvement was evaluated by both the patient and the physician to be less than expected but still with some improvement. Poor: unsatisfactory results to the patient and /or the physician. All adverse effects were checked during study.High resolution digital photographs were taken for lesions of all patients using identical camera folder setting before starting treatment, on each follow up visit and after complete recovery. Clinical improvement was evaluated by physicians. The criteria for evaluations using a quartile grading scale were: 0=no improvement. 1=mild (percent improvement, less than 25%), 2=moderate (percent improvement 25-49%), 3=good (percent improvement 50-74%), 4=excellent (percent improvement equal to or more than 75%). In addition, a patient satisfaction score was rated using the following scale, A. satisfied, B.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: June 30, 2018
• Est. primary completion date: June 20, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Tinea Versicolor infection

Exclusion Criteria:

• concomitant treatment with other medications for the same condition being studied, TVC.

• pregnancy

• lactation

• immunocompromised patients

Related Conditions & MeSH terms

• Tinea Versicolor

Intervention

Drug:
• voriconazole gel once daily
voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
• voriconazole gel twice daily
voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
• placebo
the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, voriconazole, is not added then applied twice daily in the same manner

Locations

Country	Name	City	State
Egypt	Minia University hospital	Minya	Minia

Sponsors (1)

Lead Sponsor	Collaborator
Sara Botros

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	complete cure		1-4 weeks